BioCentury | Sep 29, 2017
Financial News

Public financing roundup: Kadmon, TherapeuticsMD, GTx, Newron

...28. Kadmon's most advanced programs, autoimmune and fibrotic disease candidate KD025 and oncology therapy tesevatinib (XL647...
...KD025 is an oral selective inhibitor of Rho-associated coiled-coil containing protein kinase 2 (ROCK2) and tesevatinib...
...Fla. GTx Inc. (NASDAQ:GTXI), Memphis, Tenn. Newron Pharmaceuticals S.p.A. (SIX:NWRN), Bresso, Italy Jennie Walters enobosarm GTx-024 KD025 sarizotan Selective androgen receptor modulator tesevatinib TX-004HR XL647 Aisling...
BioCentury | Sep 27, 2017
Financial News

Public financing roundup: Kadmon, TherapeuticsMD, GTx, Newron

...Kadmon's most advanced programs, autoimmune and fibrotic disease candidate KD025 and oncology therapy tesevatinib ( XL647...
...KD025 is an oral selective inhibitor of Rho-associated coiled-coil containing protein kinase 2 (ROCK2) and tesevatinib...
...13%) to $5.28, and Newron slipped CHF1.55 (10%) to CHF14.35. GTx added $0.01 to $8.78. Jennie Walters EMD-128130 estradiol/progesterone Evenamide NW-3509 sarizotan tesevatinib TX-001HR TX-004HR Yuvvexy GTx...
BioCentury | Sep 5, 2016
Clinical News

Tesevatinib: Phase II started

...tesevatinib once daily in up to 40 patients with recurrent glioblastoma. Kadmon has rights to tesevatinib...
...New York, N.Y. Symphony Evolution Inc. , Rockville, Md. Product: Tesevatinib ( XL647 ) (formerly KD019...
BioCentury | Jul 26, 2016
Top Story

Kadmon raises $75M in IPO

...Kadmon's most advanced programs, autoimmune and fibrotic disease candidate KD025 and oncology therapy tesevatinib ( XL647...
...KD025 is an oral selective inhibitor of Rho-associated coiled-coil containing protein kinase 2 (ROCK2) . Tesevatinib...
BioCentury | Jul 14, 2016
Financial News

Kadmon updates IPO terms

...million. Its most advanced programs, autoimmune and fibrotic disease candidate KD025 and oncology therapy tesevatinib (XL647...
...KD025 is an oral selective inhibitor of Rho-associated coiled-coil containing protein kinase 2 (ROCK2) . Tesevatinib...
BioCentury | Jan 25, 2016
Clinical News

Tesevatinib: Phase II started

...Kadmon began an open-label, U.S. Phase II trial to evaluate 300 mg oral tesevatinib once daily...
...TKI and whose disease has metastasized to the brain or leptomeninges. Kadmon has rights to tesevatinib...
...New York, N.Y. Symphony Evolution Inc. , Rockville, Md. Product: Tesevatinib ( XL647 ) (formerly KD019...
BioCentury | Jul 13, 2015
Clinical News

Tesevatinib: Interim Phase Ib/IIa data

...U.S. Phase Ib/IIa trial showed that once-daily 150, 250 and 300 mg doses of oral tesevatinib...
...tesevatinib plus Herceptin. The Phase IIa portion of the trial will evaluate the MTD of tesevatinib...
...New York, N.Y. Symphony Evolution Inc. , Rockville, Md. Product: Tesevatinib ( XL647 ) (formerly KD019...
BioCentury | Jun 9, 2014
Clinical News

KD019: Phase Ib/IIa started

...Kadmon began an open-label, U.S. Phase Ib/IIa trial of once-daily oral KD019 in combination with Herceptin...
...with or without brain metastases, will evaluate multiple ascending-doses of 150, 250 and 300 mg KD019...
...Corp. LLC , New York, N.Y. Symphony Evolution Inc. , Rockville, Md. Product: KD019 , XL647...
BioCentury | Jun 6, 2013
Cover Story

Driving cancer through ErbB3

...ErbB4 Phase III Symphony Evolution Inc. / Exelixis Inc. (NASDAQ:EXEL) / Kadmon Corp. LLC XL647; KD019...
BioCentury | Mar 5, 2012
Clinical News

XL647: Phase III started

...Kadmon began a double-blind, placebo-controlled, U.S. Phase III trial to compare once-daily 300 mg oral KD019...
...use the VeriStrat test from Biodesix Inc. (Broomfield, Colo.) to identify biomarkers of response to KD019...
...Corp. LLC , New York, N.Y. Symphony Evolution Inc. , Rockville, Md. Product: XL647 , KD019...
Items per page:
1 - 10 of 51